DE60001725D1 - Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression - Google Patents

Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression

Info

Publication number
DE60001725D1
DE60001725D1 DE60001725T DE60001725T DE60001725D1 DE 60001725 D1 DE60001725 D1 DE 60001725D1 DE 60001725 T DE60001725 T DE 60001725T DE 60001725 T DE60001725 T DE 60001725T DE 60001725 D1 DE60001725 D1 DE 60001725D1
Authority
DE
Germany
Prior art keywords
saredutant
treatment
acceptable salts
pharmaceutical acceptable
heavy depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60001725T
Other languages
English (en)
Other versions
DE60001725T2 (de
Inventor
Xavier Emonds-Alt
Philippe Soubrie
Regis Steinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of DE60001725D1 publication Critical patent/DE60001725D1/de
Publication of DE60001725T2 publication Critical patent/DE60001725T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60001725T 1999-04-27 2000-04-25 Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression Expired - Lifetime DE60001725T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR9905338 1999-04-27
PCT/FR2000/001084 WO2000064423A2 (fr) 1999-04-27 2000-04-25 Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression

Publications (2)

Publication Number Publication Date
DE60001725D1 true DE60001725D1 (de) 2003-04-24
DE60001725T2 DE60001725T2 (de) 2004-02-05

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001725T Expired - Lifetime DE60001725T2 (de) 1999-04-27 2000-04-25 Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression

Country Status (33)

Country Link
US (3) US6573281B1 (de)
EP (1) EP1173179B1 (de)
JP (1) JP2002542281A (de)
KR (1) KR20020001850A (de)
CN (1) CN1172669C (de)
AR (1) AR023597A1 (de)
AT (1) ATE234617T1 (de)
AU (1) AU764304B2 (de)
BG (1) BG65472B1 (de)
BR (1) BR0010006A (de)
CA (1) CA2370834C (de)
CZ (1) CZ294904B6 (de)
DE (1) DE60001725T2 (de)
DK (1) DK1173179T3 (de)
EE (1) EE05211B1 (de)
ES (1) ES2193065T3 (de)
FR (1) FR2792835B3 (de)
HK (1) HK1041821A1 (de)
HU (1) HUP0200969A3 (de)
IL (1) IL145269A0 (de)
MX (1) MXPA01010904A (de)
NO (1) NO20015228L (de)
NZ (1) NZ513851A (de)
PL (1) PL196479B1 (de)
PT (1) PT1173179E (de)
RU (1) RU2238726C2 (de)
SI (1) SI1173179T1 (de)
SK (1) SK285459B6 (de)
TR (1) TR200102512T2 (de)
TW (1) TWI225399B (de)
UA (1) UA69441C2 (de)
WO (1) WO2000064423A2 (de)
ZA (1) ZA200107143B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
AU2001244999A1 (en) * 2000-04-06 2001-10-23 Astrazeneca Ab Naphthamide neurokinin antagonists for use as medicaments
WO2001077089A1 (en) * 2000-04-06 2001-10-18 Astrazeneca Ab New neurokinin antagonists for use as medicaments
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
AU2008297251A1 (en) * 2007-09-14 2009-03-19 F. Hoffmann-La Roche Ag Piperidine derivatives as NK3 receptor antagonists
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
SI1173179T1 (en) 2003-06-30
SK15472001A3 (sk) 2002-03-05
PL196479B1 (pl) 2008-01-31
HUP0200969A2 (hu) 2002-07-29
IL145269A0 (en) 2002-06-30
TR200102512T2 (tr) 2002-04-22
US20030176462A1 (en) 2003-09-18
US7390823B2 (en) 2008-06-24
EP1173179A2 (de) 2002-01-23
US6573281B1 (en) 2003-06-03
BG65472B1 (bg) 2008-09-30
CN1172669C (zh) 2004-10-27
ZA200107143B (en) 2002-10-30
EE200100553A (et) 2003-02-17
RU2238726C2 (ru) 2004-10-27
TWI225399B (en) 2004-12-21
WO2000064423A3 (fr) 2001-04-19
JP2002542281A (ja) 2002-12-10
FR2792835B3 (fr) 2001-05-25
EP1173179B1 (de) 2003-03-19
PT1173179E (pt) 2003-06-30
CA2370834A1 (en) 2000-11-02
NO20015228D0 (no) 2001-10-25
AU4303400A (en) 2000-11-10
HUP0200969A3 (en) 2004-03-01
SK285459B6 (sk) 2007-02-01
NO20015228L (no) 2001-12-21
EE05211B1 (et) 2009-10-15
MXPA01010904A (es) 2002-06-21
AR023597A1 (es) 2002-09-04
FR2792835A1 (fr) 2000-11-03
ATE234617T1 (de) 2003-04-15
US20080227818A1 (en) 2008-09-18
CA2370834C (en) 2007-09-25
KR20020001850A (ko) 2002-01-09
CZ20013812A3 (cs) 2002-02-13
CN1348371A (zh) 2002-05-08
BR0010006A (pt) 2002-01-15
CZ294904B6 (cs) 2005-04-13
NZ513851A (en) 2003-04-29
ES2193065T3 (es) 2003-11-01
AU764304B2 (en) 2003-08-14
DE60001725T2 (de) 2004-02-05
HK1041821A1 (en) 2002-07-26
WO2000064423A2 (fr) 2000-11-02
UA69441C2 (uk) 2004-09-15
DK1173179T3 (da) 2003-07-14
BG105962A (en) 2002-05-31
PL351922A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE69913520D1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69806801T2 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR